Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions.
Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions.
复制标题
转移性肾细胞癌的靶向治疗：当前治疗和未来方向。
DOI：
10.1177/1758834009352498
复制
发表时间：
2010-01-01
影响因子：
4.9
通讯作者：
Chi, Kim N
中科院分区：
文献类型：
--
作者：
Heng, Daniel Y C;Kollmannsberger, Christian;Chi, Kim N
An understanding of vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways has greatly changed the way metastatic renal cell carcinoma (RCC) is treated. Based on available phase III randomized trials, anti-VEGF agents such as sunitinib, sorafenib, bevacizumab-based therapy, and mTOR-targeted agents such as temsirolimus and everolimus have been used in the treatment armamentarium for this disease. Now that agents directed against these pathways have largely replaced immunotherapy as the standard of care, new questions have emerged and are the subject of ongoing clinical trials. The development of new targeted therapies including axitinib, pazopanib, cediranib, volociximab, tivozanib (AV-951), BAY 73-4506, and c-met inhibitors such as GSK1363089 and ARQ197 may potentially expand the list of treatment options. Sequential and combination targeted therapies are currently under investigation in advanced disease as are adjuvant and neo-adjuvant approaches around nephrectomy.
